SCHEMBL4666099

SCHEMBL4666099

CN1CCN(CCCn2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccccc5F)cc4)ncn3)c3ccccc32)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 3/20 0.41
PRKCA P17252 3/20 0.41
KDR P35968 3/20 0.38
FLT4 P35916 2/20 0.38
FLT1 P17948 1/20 0.38
IGF1R P08069 1/20 0.37
CDK2 P24941 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
HTR6 P50406 1/20 0.36
GSK3B P49841 3/20 0.36
AXL P30530 2/20 0.35
EGFR P00533 4/20 0.34
QPCT Q16769 2/20 0.34
PRKCE Q02156 1/20 0.34
CDK9 P50750 1/20 0.34
MET P08581 1/20 0.33
ABCB1 P08183 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
AURKA O14965 2/20 0.33
PDGFRB P09619 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667452 0.94 PRKCB (0.40) PRKCBPRKCAKDRFLT4FLT1
SCHEMBL4665742 0.88 PRKCB (0.40) PRKCBPRKCAKDRFLT4FLT1
SCHEMBL4667477 0.88 EGFR (0.35) PRKCBPRKCAEGFRPRKCECDK9
Formic Acid SCHEMBL4666097 0.85 PRKCB (0.43) PRKCBPRKCAKDRFLT4FLT1
SCHEMBL4665759 0.84 ABL1 (0.36) AXLEGFRUSP2ALDH1A1CYP1A2
SCHEMBL4663993 0.83 ABL1 (0.42) AXLAURKAPDGFRBAURKBUSP2
SCHEMBL4665992 0.82 CYP1A2 (0.35) PRKCAHTR6EGFRCDK9ABCB1
SCHEMBL4666179 0.82 PRKCA (0.35) PRKCBPRKCAEGFRPRKCECDK9
SCHEMBL4664335 0.81 ABL1 (0.43) KDRUSP2ALDH1A1CYP1A2CYP2D6
SCHEMBL4665713 0.80 ABL1 (0.37) IGF1RCDK2DYRK1BEGFRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 PRKCB 337/4885PRKCA 349/4885KDR 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.